New president & CEO at Marinus Pharmaceuticals
This article was originally published in Scrip
Marinus Pharmaceuticals (US), a developer of therapeutics to treat neurological, psychiatric and pain disorders, has appointed John Krayacich president and chief executive officer. He will be responsible for leading the company's drug and business development for ganaxolone, an adult and paediatric epilepsy candidate in Phase II development, and chelerythrine, a preclinical schizophrenia candidate. Mr Krayacich most recently was with Novartis Pharmaceuticals, where he served as global programme head for the antidepressant agomelatine, and vice-president and global head of neuroscience project management.